Immune modulation and dysregulation in MDS and AML

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub was delighted to speak to Steering Committee Member Naval Daver, MD Anderson Cancer Center, Houston, US, about immune modulation and dysregulation in MDS and AML.

Immune therapy has emerged as a major treatment approach to both solid tumors and hematological malignancies over the past 15 years, but is less advanced in the MDS/AML setting. Here, Naval Daver highlights the novel targets and therapeutic agents that are being used to modulate immune responses and address immune dysregulation in MDS and AML.